Ligand Pharmaceuticals Incorporated
Records under this name other than the patents Ligand Pharmaceuticals Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 85 patents it holds.
Back to Ligand Pharmaceuticals Incorporated
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,241,650 | Device, Method, and Use for Treatment of Neuropathy Involving Nitric Oxide Formerly held In force · High confidence | In force | High confidence | |
| US 9,427,605 | Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor Formerly held In force · High confidence | In force | High confidence | |
| US 7,314,887 | Thrombopoietin activity modulating compounds and methods Term ended Term ended Oct 21, 2025 · USPTO record | Term ended | Term ended Oct 21, 2025 | USPTO record |
| US 8,865,918 | Androgen receptor modulator compounds and methods Term ended Ended no later than Mar 11, 2025 · USPTO record | Term ended | Ended no later than Mar 11, 2025 | USPTO record |
| US 9,359,285 | Androgen receptor modulator compounds and methods Term ended Ended no later than Mar 11, 2025 · USPTO record | Term ended | Ended no later than Mar 11, 2025 | USPTO record |
| US 7,071,205 | 5-cycloalkenyl 5H-chromeno[3,4-f]quinoline derivatives as selective progesterone receptor modulator compounds Term ended Term ended Oct 10, 2023 · USPTO record | Term ended | Term ended Oct 10, 2023 | USPTO record |
| US 7,084,151 | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5H-chromeno[3,4-ƒ]quinolines as selective progesterone receptor modulator compounds Term ended Term ended Oct 10, 2023 · USPTO record | Term ended | Term ended Oct 10, 2023 | USPTO record |
| US 9,144,557 | Hematopoietic growth factor mimetic small molecule compounds and their uses Lapsed on the fee record Ended Sep 29, 2023 · USPTO record | Lapsed on the fee record | Ended Sep 29, 2023 | USPTO record |
| US 7,214,690 | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods Term ended Term ended Aug 7, 2023 · USPTO record | Term ended | Term ended Aug 7, 2023 | USPTO record |
| US 6,992,108 | Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor Formerly held Term ended Term ended Jan 31, 2023 · USPTO record | Term ended | Term ended Jan 31, 2023 | USPTO record |